Ipsen: Dysport, First Botulinum Toxin Effective in Phase III Against Migraine
On July 9, 2026, Ipsen announced positive Phase III results for Dysport in the prevention of both episodic and chronic migraine, becoming the first laboratory to demonstrate the effectiveness of a botulinum toxin for these two indications.
The E-BEOND and C-BEOND trials, which enrolled 1,510 patients across 120 centers, both achieved their primary endpoint: a statistically significant reduction in the monthly number of migraine days compared to placebo, measured between weeks 21 and 24. These results mark a first: Dysport is the first botulinum toxin to show statistically significant efficacy in Phase III for episodic migraine (defined as 6 to 14 migraine days per month). The BEOND program thus becomes the first Phase III study program to demonstrate the efficacy of a botulinum toxin in preventing both forms of the disease.
Tolerance Profile Consistent with Established Data
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Dysport was well tolerated in both trials. The safety signals observed are consistent with the known profile of the product for its approved indications, with no new or unexpected signals identified. The BEOND trial extension program, in which all participants receive Dysport for two treatment cycles, will continue until week 48. Detailed results will be presented at a later scientific congress.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1074.9M€
Guidance from the release
Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
